Day 1, week 1 and week 12 data from patient daily diaries
| PRO measures | Day 1 median (IQR) | Week 1 median (IQR) | Week 12 median (IQR) | ||||||
| Placebo (n=488) | Baricitinib (n=487) | Adalimumab (n=330) | Placebo (n=488) | Baricitinib (n=487) | Adalimumab (n=330) | Placebo (n=488) | Baricitinib (n=487) | Adalimumab (n=330) | |
| Duration of morning joint stiffness, minutes, median (IQR) | 60.0 (30.0, 180.0) | 60.0 (30.0, 180.0) | 60.0 (20.0, 180.0) | 87.5 (32.5, 180.0) | 75.0† (27.5, 154.3) | 60.0*** (20.0, 150.0) | 60.0 (17.1, 154.3) | 27.1*** † (4.3, 90.0) | 36.6*** (9.2, 120.0) |
| Day 1 (mean (SD)) | Week 1 LSM (95% CI) | Week 12 LSM (95% CI) | |||||||
| Severity of morning joint stiffness | 5.5 (2.2) | 5.4 (2.2) | 5.3 (2.3) | 5.3 (5.1 to 5.4) | 4.8*** (4.6 to 4.9) | 4.7*** (4.5 to 4.8) | 4.1 (3.9 to 4.3) | 3.0*** †† (2.8 to 3.2) | 3.5*** (3.2 to 3.7) |
| Worst Tiredness | 5.6 (2.2) | 5.6 (2.2) | 5.5 (2.2) | 5.3 (5.1 to 5.4) | 4.9*** (4.7 to 5.0) | 4.8*** (4.7 to 5.0) | 4.3 (4.1 to 4.5) | 3.6 *** † (3.4 to 3.8) | 3.9** (3.6 to 4.1) |
| Worst Joint Pain | 5.9 (2.1) | 5.9 (2.1) | 5.7 (2.2) | 5.6 (5.5 to 5.8) | 5.0*** (4.9 to 5.2) | 5.1*** (4.9 to 5.2) | 4.6 (4.4 to 4.8) | 3.4*** ††† (3.2 to 3.6) | 4.0*** (3.8 to 4.2) |
*p≤0.05; **p≤0.01; ***p≤0.001 versus placebo.
†p≤0.05, ††p≤0.01; †††p≤0.001 versus adalimumab.
LSM, least squares mean; PRO, patient-reported outcome.